Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LNZA | 8-K | mixed | 6/10 | LanzaTech reported Q2 2026 revenue of $9.0M (flat YoY) but operating expenses dropped 67% to $11.7M, driving a 74% impro | Aug 14, 2026 |
| GALT | 8-K | bullish | 8/10 | Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headli | Aug 14, 2026 |
| BYND | 8-K | bearish | 5/10 | Beyond Meat effected a 1-for-30 reverse stock split and reduced authorized shares from 3B to 100M to regain Nasdaq compl | Aug 14, 2026 |
| ACCO | 8-K | bullish | 6/10 | ACCO Brands announced a definitive agreement to acquire Trust (GXT Holding B.V.), a European computer and gaming accesso | Aug 14, 2026 |
| CABO | 8-K | neutral | 3/10 | Cable One appointed Heather McCallion as Chief Operating Officer, effective August 24, 2026. This is a routine senior le | Aug 14, 2026 |
| TVRD | 8-K | mixed | 5/10 | Tvardi Therapeutics reported Q2 2026 EPS of $(0.69), a 6.2% miss vs consensus of $(0.65), with no revenue. The company a | Aug 14, 2026 |
| TMS | 8-K | mixed | 5/10 | Teamshares reported Q2 2026 revenue of $148.7M (+20% YoY) and a GAAP net income of $9.5M, swinging from a -$12.9M loss a | Aug 14, 2026 |
| NMRA | 8-K | neutral | 4/10 | Neumora Therapeutics reported Q2 2026 results with a net loss of $43.1M ($0.23 per share), in line with consensus estima | Aug 14, 2026 |
| RFAI | 8-K, 425 | bearish | 6/10 | RF Acquisition Corp II shareholders approved a six-month extension of the business combination deadline to February 15, | Aug 14, 2026 |
| PWCM | 8-K | bearish | 6/10 | PowerCompute (PWCM) reported Q2 2026 revenue of $2.1M (+9.8% YoY) but swung to a net loss of $4.6M from a $0.1M profit a | Aug 14, 2026 |
| FOCL | 8-K | bearish | 6/10 | EDAP TMS S.A. (FOCL) entered into an underwriting agreement for a public offering of 8,425,000 ADSs at $4.75 per ADS, wi | Aug 14, 2026 |
| ARX | DEFA14A, 8-K | bullish | 7/10 | Thoma Bravo (through Cherry Tree BidCo) will acquire Accelerant Holdings for $20.25 per share in cash, a ~47% premium to | Aug 14, 2026 |
| ASST | 8-K | neutral | 2/10 | Strive, Inc. filed an 8-K announcing that its board maintained the 13.00% annual dividend rate on its Series A Perpetual | Aug 14, 2026 |
| DOMH | 8-K | bullish | 4/10 | Dominari Holdings entered into inducement agreements with holders of Series A warrants to reduce market overhang and rai | Aug 14, 2026 |
| BGMS | 8-K | bearish | 8/10 | BGMS reported Q2 2026 revenue of $336,000 (fire safety distribution) and a net loss of $405,000, improving from a $1.3M | Aug 14, 2026 |
| EIKN | 8-K | neutral | 3/10 | Eikon Therapeutics filed an 8-K on August 13, 2026, furnishing an updated corporate presentation (Exhibit 99.1) that hig | Aug 14, 2026 |
| CMCT | 8-K | bearish | 6/10 | CMCT reported Q2 2026 results with total revenue of $29.7M (slightly beating $28.1M consensus) but FFO per share of $(1. | Aug 14, 2026 |
| PFSA | 8-K | neutral | 3/10 | Profusa announced a 1-for-4 reverse stock split effective August 17, 2026, reducing outstanding shares from 2,422,906 to | Aug 14, 2026 |
| NUTX | 8-K | bullish | 6/10 | The Fifth Circuit en banc vacated key provisions of the July 2021 interim final rule under the No Surprises Act, prohibi | Aug 13, 2026 |
| GOSS | 8-K | neutral | 5/10 | Gossamer Bio reported Q2 2026 GAAP net income of $16.9 million ($0.05 basic EPS) vs. a net loss of -$38.3 million (-$0.1 | Aug 13, 2026 |
| DARE | 8-K | mixed | 5/10 | Dare Bioscience reported Q2 2026 results with a net loss of -$0.20 per share, beating consensus estimates of -$0.33 by 3 | Aug 13, 2026 |
| FOCL | 8-K | mixed | 6/10 | FocalTherics (FOCL) reported strong Q2 2026 HIFU continuing operations revenue of $13.2M (+39% YoY), with 13 Focal One s | Aug 13, 2026 |
| SLXN | 8-K | bearish | 6/10 | Silexion Therapeutics Corp entered into a securities purchase agreement on August 11, 2026, to sell up to $2,500,005 of | Aug 13, 2026 |
| HTFL | 8-K | bullish | 6/10 | Heartflow reported Q2 2026 revenue of $64.1M, a 48% YoY increase, beating the $56.6M consensus. GAAP EPS was -$0.18 vs c | Aug 13, 2026 |
| TMC | 8-K | bearish | 6/10 | TMC reported Q2 2026 results with a net loss of $60.1M ($0.14/share), significantly wider than the consensus estimate of | Aug 13, 2026 |
| SMSI | 8-K | neutral | 4/10 | Smith Micro Software reported Q2 2026 revenue of $4.3M, slightly down from $4.4M a year ago, and a GAAP net loss of $2.7 | Aug 13, 2026 |
| OPLN | 8-K | bearish | 6/10 | Apax Partners (Ignition Acquisition Holdings LP) completed a secondary offering of 8,000,000 OPLN shares at $34.36/share | Aug 13, 2026 |
| WRLD | 8-K | neutral | 3/10 | World Acceptance Corp announced a new $50.0 million share repurchase authorization on August 13, 2026. The program is a | Aug 13, 2026 |
| GVA | 8-K | bullish | 6/10 | Granite Construction completed the redemption of its $273.7M 3.75% Convertible Senior Notes due 2028 by paying ~$715M in | Aug 13, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $650,000 under its existing $50M revolving credit facility with Parkview Holdings | Aug 13, 2026 |